[{"orgOrder":0,"company":"Turn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Petrolatum","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Turn Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Turn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Turn Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Turn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Turn Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Turn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Turn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Turn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"GX-03","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Turn Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Turn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Turn Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Turn Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The study evaluated the immunological inhibitory effects of the topical application of Turn Therapeutics' candidate, GX-03, in an eczema model using C57BL/6 mice.

                          Brand Name : GX-03

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 05, 2024

                          Lead Product(s) : GX-03

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The proceeds will fund clinical trials of its FDA-cleared antimicrobial ointment for two potential new drug indications: moderate to severe eczema and onychomycosis, or toenail fungus.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 22, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Hexagen contains broad-spectrum, liquid antimicrobials with strong antiviral activity suspended in petrolatum. The trial will assess Hexagen’s ability to prevent COVID-19 infection in frontline workers when worn intranasally as an adjunct to personal p...

                          Brand Name : Hexagen

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 21, 2021

                          Lead Product(s) : Petrolatum

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank